D. E. Shaw & Co. Inc. Sells 168,241 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

D. E. Shaw & Co. Inc. decreased its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 47.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 184,117 shares of the company's stock after selling 168,241 shares during the period. D. E. Shaw & Co. Inc. owned 0.22% of Syndax Pharmaceuticals worth $2,434,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in SNDX. Barclays PLC raised its stake in shares of Syndax Pharmaceuticals by 143.4% in the 3rd quarter. Barclays PLC now owns 187,629 shares of the company's stock worth $3,612,000 after buying an additional 110,535 shares in the last quarter. Jump Financial LLC raised its position in Syndax Pharmaceuticals by 80.8% in the fourth quarter. Jump Financial LLC now owns 173,890 shares of the company's stock worth $2,299,000 after acquiring an additional 77,699 shares in the last quarter. Simplify Asset Management Inc. raised its position in Syndax Pharmaceuticals by 20.8% in the fourth quarter. Simplify Asset Management Inc. now owns 147,641 shares of the company's stock worth $1,952,000 after acquiring an additional 25,456 shares in the last quarter. Northern Trust Corp lifted its holdings in Syndax Pharmaceuticals by 7.5% in the 4th quarter. Northern Trust Corp now owns 792,750 shares of the company's stock valued at $10,480,000 after acquiring an additional 55,144 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Syndax Pharmaceuticals by 594.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 331,300 shares of the company's stock valued at $4,378,000 after purchasing an additional 283,577 shares in the last quarter.

Syndax Pharmaceuticals Trading Down 8.9%

NASDAQ SNDX traded down $0.96 during trading on Monday, reaching $9.85. 3,902,175 shares of the company's stock were exchanged, compared to its average volume of 1,774,576. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $8.58 and a fifty-two week high of $25.07. The company's fifty day simple moving average is $11.76 and its 200-day simple moving average is $13.61. The firm has a market capitalization of $847.56 million, a PE ratio of -2.71 and a beta of 0.82.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.04) by $0.06. The company had revenue of $20.04 million during the quarter, compared to analysts' expectations of $15.88 million. During the same period last year, the company earned ($0.85) earnings per share. Syndax Pharmaceuticals's revenue for the quarter was up 1900.0% compared to the same quarter last year. Equities analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Analyst Ratings Changes

SNDX has been the topic of a number of research reports. JPMorgan Chase & Co. boosted their target price on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a report on Thursday, March 20th. Wall Street Zen raised Syndax Pharmaceuticals to a "sell" rating in a report on Tuesday, May 6th. Citigroup reduced their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Scotiabank boosted their target price on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a research report on Tuesday, May 6th. Finally, HC Wainwright reiterated a "buy" rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $35.91.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).